These findings provide the rationale for this first-in-human study of oleclumab alone or in combination with the anti-PD-L1 monoclonal antibody durvalumab in patients with advanced CRC, PDAC, or EGFRm non-small-cell lung cancer (NSCLC) given the high expression of CD73 and its association with poor prognosis in these tumor types. Here, NT5E is linked to neoplasm.